AGENDA
18:00 - 18:05 Dr TOUAHRIA ABDELKRIM
Introduction
18:05 - 18:35 Pr Daoudi Smail
La sclèrose en plaques en Algérie etats des lieux
18:35 - 19:05 Pr Amine Aissaoui
L’aspect pharmaco économique des traitements de la sclérose en plaques en Algérie
19:05 - 19:20 All
Discussion débat
19:20 - 19:50 Pr Aissaoui /ALL
Workshop : évaluation de l’ impact budgétaire des traitements de la sep: cas pratiques
19:50 - 20:05 Pr Amine Aissaoui
Etude Algérienne « l’impact budgétaires traitements de la sep » : méthodologie et résultats
ORATEURS
Dr. Touahria Abdelkrim
- Président de l’Ordre Régional des Pharmaciens d’Alger
- Président de l’Ordre National des Pharmaciens
- Président du Conseil National de Déontologie Médicale
- Membre de la Commission Nationale de veille et de suivi de l’évolution de l’épidémie du Coronavirus (COVID-19)
- Président de Inter Ordre des Pharmaciens d’Afrique
- Membre du conseil de la Conférence Internationale des Ordres des Pharmaciens Francophones
- Membre du conseil de l’Inter-Ordre des Pharmaciens Maghrébins
- Docteur en Pharmacie, affaires, gestion, marketing et services de soutiens apparentés
- Doctorat en pharmacie (Pharm D) (1991-1986 Fac central Gestion pharmaceutique
- PHARMACIE Touahria installée depuis Mars 1992 préparations magistrales. Conseils en dermocosmetique
- Snapo groupement pharmaceutique Président de la section ordinale régionale des pharmaciens d’Alger
Pr Daoudi Smail
Consultant Neurologist and Head of Neurology Department- Prof. Smail Daoudi is Associate Professor of neurology and head of the Neurology Department since 2006 at Nedir Mohammed Teaching Hospital in Tizi-ouzou located in north center of Algeria. After completing his medical residency in the capital Algiers, he held a position for a Fellowship Program at Pitie Salpetriere Teaching Hospital in Paris and after in Haute Pierre Teaching Hospital in Strasbourg, France. From that experience he shown a research interest for inflammatory CNS diseases, particularly for Multiple sclerosis and has authored many articles. He has developed a multidisciplinary unit specialized in the management of multiple sclerosis for a total of 1300 patients until today. In addition, he is part of several panels experts at the regional and international level, in particular for the management of pain and since this year he is a member of the Applied Research Committee of the WFN.
Pr Amine Aissaoui
- PhD in Economics
- Doctor of Pharmacy
- Master in Health Economics
- Master in Health Law and Policy
- RESEARCH ASSOCIATE in PHARMACEUTICAL ECONOMICS AND POLICY- PARIS DAUPHINE, PSL_ VISITING TEACHER AT FACULTY PHARAMCIE MARSEILLE_CONSULTANCY ACTIVITIES FOR PHARMACEUTICAL and MEDTECH.
- TEACHING ACTIVITIES: ‐ MASTER II: Évaluation médico-économique et accès au marché EMAM Paris Dauphine University, PSL o Empirical approaches to prices analysis - courses from 2016 ‐ MASTER I: économie et gestion de la santé Paris Dauphine University, PSL o Introduction to Pharmaceutical Economics and Policy - courses from 2019 ‐ MASTER I-II : Etudiants 5ème année Pharmacie mention industries – Pharmacy Marseille-University o Introduction to market access and Health economics from – courses from2017
- ADC -CABINET D’ÉTUDES ÉCONOMIQUES ET POLITIQUES PUBLIQUES – HEAD OF ECONOMICS AFFAIRS IN DEPARTMENT OF LIFE SCIENCE (FROM 2018, PARIS) ‐ Provides strategic and methodologic supports to Pharmaceutical Company Designing prices strategy within pricing negotiation including the support clients in their discussion front of the French Economics Committee for Health Products (CEPS). o Price positioning strategy and propose o Pricing analysis for innovative to allow valorization arguments, and positioning rational (Managed Entry Agreements) ‐ Develops a set of reports on pharmaceutical market: o The access of orphan drug in France from ATU to CEPS o The impact of biosimilar drugs in France o The Hospital market in France retrospective study from 2016-2019 ‐ Embassy of France in USA (Washington DC) Provide a regular input related pharmaceutical policy system in France: Report related handling cut prices, conventional French system (Accord cadre CEPS-LEEM).
- RESEARCHER-CONTRACTOR in MARKET ACCESS and HEOR (2013-2018 PARIS) As researcher, I was contractor supporting big pharm as well as consultants for their market access and HEOR for various clients: ‐ For Vaccines: Developed literature review of Economic evaluation and economic burden for influenza vaccination: Provided an Economic summary / Conducted quality check for model adaptations (Economic impact + Budget impact model) for Flu disease: Reviewed the Economic models + the technical reports adapted for affiliate (Europe, LATAM) / Supported the project preparation for drug candidate (pricing assessment, unmet need evaluation) ‐ For oncology drug: Adapted cost-effectiveness and budget impact models for French submissions / Prepared submission dossier for CEESP and CEPS /Carried out the Technical review with HTA authority (Echange technique avec CEESP) / Costing, research DRG, review economic evidence for Value communication in France / Adapted Value Communication Materials to the French market ‐ Ministry of social security (Algeria) Invited to present the international implementations and experiences of managed entry agreement and risk sharing schemes / To discuss about the Decree related the Managed Entry agreement - For psychosis and neurological drugs: Support the strategy of launch product: Submission Dossier to HTAs and Support to Pricing & Reimbursement for affiliates (Europe: Nordic countries, Central and Eastern regions) / Prepare the Economic Model adaptations: Cost effectiveness and Budget impact model / Coordinated internal activity with the others departments / Conduct a literature review in neurology (Europe+ US) - Anti-rheumatic osteoarthritis joints drug: Developed a Cost minimization analysis for anti-rheumatic osteoarthritis joints / Prepared literature review and economic summary
- EY AS SENIOR CONSULTANT AT ACTUARIAL DEPARTMENT (2013-2014, PARIS) - Proposed actuarial services to private organizations in life sciences (EFPIA, LEEM, G5 santé) / organized meeting with French Health authorities (Ministry of health, ANSM, CNAMTS) / Prepared and submitted tender dossier for NGO (World bank, WHO, AFD) / Managed junior consultants
- IPSEN PHARM AS MARKET ACCESS ANALYST, AT GLOBAL PRICING & MARKET ACCESS DEPARTMENT (2010 -2012 PARIS) ‐ For oncology drug: Supported local and global (EU5) market access for value propositions in prostate cancer / Involved in the literature review to support the value communication / Provided a Landscaping of pricing regulation in EU5: Perform review for HTA reforms / Assisted in the preparation of meetings: Key Affiliate Team (KAT) meetings, Affiliate Network Meeting (Market access community).
INSCRIPTION
Numéro de la réunion : 175 653 7924
Mot de passe : MERCK
App Webex
Veuillez télécharger l’application webex selon votre device.
Une fois téléchargée, merci de revenir vers l’email que vous avez reçu et cliquer sur le
lien pour accéder à la salle du webinar
En cas de non réception du mail, veuillez consulter vos spams
Contact